Loading clinical trials...
Loading clinical trials...
A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma
Conditions
Interventions
Aflibercept (Eylea, BAY 86-5321)
Sham Injection
Locations
19
Japan
Yoshida, Fukui, Japan
Gifu, Gifu, Japan
Amagasaki, Hyōgo, Japan
Himeji, Hyōgo, Japan
Kobe, Hyōgo, Japan
Kanazawa, Ishikawa-ken, Japan
Start Date
April 2, 2015
Primary Completion Date
June 16, 2016
Completion Date
September 6, 2016
Last Updated
September 15, 2017
NCT03187418
NCT02647515
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions